Serum Uric Acid Levels and Non-Motor Symptoms in Parkinson's Disease.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2020
Historique:
pubmed: 24 5 2020
medline: 20 8 2021
entrez: 24 5 2020
Statut: ppublish

Résumé

Previous studies have identified low serum uric acid (SUA) levels as a risk factor for the development of Parkinson's disease (PD). Prodromal PD mainly manifests as a complex of non-motor features, but the association between SUA levels and nonmotor symptoms (NMS) burden level in advanced PD patients is poorly studied. To determine the association between SUA levels and NMS in PD patients. Data were gathered from an open label, cross sectional, study with analysis of SUA levels in 87 PD patients and were correlated to NMS through the NMS scale (NMSS). In addition, we examined the possible relation between SUA and NMS burden levels and motor scores. There was a moderate negative association between SUA levels and NMSS total score (ρ= -0.379, p < 0.001). In line with this, we observed that higher NMS burden was associated with lower SUA levels (p < 0.001). Within individual NMSS domains, a moderate negative correlation was observed between SUA levels and the cardiovascular/falls (ρ= -0.285, p = 0.008), sleep/fatigue (ρ= -0.299, p = 0.005), and miscellaneous domains (ρ= -0.318, p = 0.003). In this observational study we observed that SUA levels were negatively associated to NMS burden in PD patients with a specific link to miscellaneous, sleep/fatigue and cardiovascular domains of the NMSS. Interestingly, we did not find a clear relation between SUA and motor scores. Future large-scale prospective studies in de novo and advanced PD are needed to evaluate and establish these associations.

Sections du résumé

BACKGROUND
Previous studies have identified low serum uric acid (SUA) levels as a risk factor for the development of Parkinson's disease (PD). Prodromal PD mainly manifests as a complex of non-motor features, but the association between SUA levels and nonmotor symptoms (NMS) burden level in advanced PD patients is poorly studied.
OBJECTIVE
To determine the association between SUA levels and NMS in PD patients.
METHODS
Data were gathered from an open label, cross sectional, study with analysis of SUA levels in 87 PD patients and were correlated to NMS through the NMS scale (NMSS). In addition, we examined the possible relation between SUA and NMS burden levels and motor scores.
RESULTS
There was a moderate negative association between SUA levels and NMSS total score (ρ= -0.379, p < 0.001). In line with this, we observed that higher NMS burden was associated with lower SUA levels (p < 0.001). Within individual NMSS domains, a moderate negative correlation was observed between SUA levels and the cardiovascular/falls (ρ= -0.285, p = 0.008), sleep/fatigue (ρ= -0.299, p = 0.005), and miscellaneous domains (ρ= -0.318, p = 0.003).
CONCLUSION
In this observational study we observed that SUA levels were negatively associated to NMS burden in PD patients with a specific link to miscellaneous, sleep/fatigue and cardiovascular domains of the NMSS. Interestingly, we did not find a clear relation between SUA and motor scores. Future large-scale prospective studies in de novo and advanced PD are needed to evaluate and establish these associations.

Identifiants

pubmed: 32444561
pii: JPD201988
doi: 10.3233/JPD-201988
doi:

Substances chimiques

Uric Acid 268B43MJ25

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1003-1010

Auteurs

Daniel J van Wamelen (DJ)

King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom.
Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, United Kingdom.
Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Department of Neurology, Nijmegen, the Netherlands.

Raquel N Taddei (RN)

King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom.
Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, United Kingdom.

Alexander Calvano (A)

King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom.
Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, United Kingdom.

Nataliya Titova (N)

Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Federal Medical Biological Agency, Department of Neurology, Neurosurgery and Medical Genetics, Moscow, Russia.
Federal State Budgetary Institution «Federal center of brain and neurotechnologies» of the Ministry of Health of the Russian Federation, Department of Neurodegenerative Diseases, Moscow, Russia.

Valentina Leta (V)

King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom.
Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, United Kingdom.

Igor Shtuchniy (I)

Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Federal Medical Biological Agency, Department of Neurology, Neurosurgery and Medical Genetics, Moscow, Russia.

Peter Jenner (P)

King's College London, Institute of Pharmaceutical Science, Hodgkin Building, Guy's Campus, London, United Kingdom.

Pablo Martinez-Martin (P)

Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.

Elena Katunina (E)

Federal State Autonomous Educational Institution of Higher Education «N.I. Pirogov Russian National Research Medical University» of the Federal Medical Biological Agency, Department of Neurology, Neurosurgery and Medical Genetics, Moscow, Russia.
Federal State Budgetary Institution «Federal center of brain and neurotechnologies» of the Ministry of Health of the Russian Federation, Department of Neurodegenerative Diseases, Moscow, Russia.

K Ray Chaudhuri (KR)

King's College London, Department of Neurosciences, Institute of Psychiatry, Psychology & Neuroscience, De Crespigny Park, London, United Kingdom.
Parkinson Foundation Centre of Excellence, King's College Hospital, Denmark Hill, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH